GP2 is a product and a source of collaboration. The individuals and groups that contribute to GP2 drive its strategy, its operations, and ultimately its impact. Read more.
At GP2, we are committed to creating a global research community with the tools and infrastructure to address emerging research needs and questions. Read more.
GP2 develops and maintains tools that assemble clinical and genetic data to help accelerate research across the Parkinson’s Disease Research community. Read more.
Latinos have varying European ancestry levels, impacting mutation frequency in LRRK2 gene. Countries with less European genetic material, like Peru, show lower mutation rates in patients.
A Blueprint for Training and Development in GP2
GP2 aims to support Parkinson’s disease research by promoting open science and data accessibility. Funded by ASAP, it focuses on improving understanding and treatments through active promotion and measurement of success.
Precision Medicine in Parkinson’s Disease: Past Lessons and New Frontiers
GP2 Trainee Network members attended a conference on Precision Medicine in Parkinson’s Disease, focusing on advancing knowledge of PD and related disorders globally.
Our website uses cookies to improve experiences and optimize our website. For more information, visit our privacy policy page
